Shenzhen Hepalink Pharmaceutical Group Overview
- Founded
-
1998

- Status
-
Public
- Employees
-
2,000

- Stock Symbol
-
002399

- Investments
-
13
- Share Price
-
$2.56
- (As of Wednesday Closing)
Shenzhen Hepalink Pharmaceutical Group General Information
Description
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in the supply of heparin sodium drugs. The company distributes its products both in the domestic and overseas markets. Its projects portfolio includes National Bio-High Technology Industrialization Demonstration, the National Torch Program, and the National Key Technology Innovation Project. The Group mainly operates three main business segments, including Finished dose pharmaceutical products business; Active pharmaceutical ingredients; and CDMO business.
Contact Information
Website
www.hepalink.com
Formerly Known As
Shenzhen Hepalink Pharmaceutical
Ownership Status
Publicly Held
Financing Status
Private Equity-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
SHE
Primary Office
- Number 21, Langshan Road, Songping Mountain
- Shenzhen, Guangdong Sheng 518057
- China
+86 0755 0000 0000
Shenzhen Hepalink Pharmaceutical Group Stock Performance
(As of Wednesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$2.56 | $2.56 | $1.65 - $2.97 | $3.4B | 1.47B | 6.6M | $0.04 |
Shenzhen Hepalink Pharmaceutical Group Financials Summary
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 3,278,526 | 3,806,527 | 3,949,172 | 4,148,737 |
Revenue | 1,090,761 | 985,767 | 771,801 | 669,305 |
EBITDA | 72,539 | 104,038 | 267,044 | 257,996 |
Net Income | 51,715 | 37,290 | 148,251 | 153,316 |
Total Assets | 3,166,314 | 2,997,784 | 2,912,142 | 2,194,138 |
Total Debt | 996,971 | 887,057 | 864,047 | 916,594 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Shenzhen Hepalink Pharmaceutical Group Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Shenzhen Hepalink Pharmaceutical Group Patents
Shenzhen Hepalink Pharmaceutical Group Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20210032376-A1 | Glycosaminoglycan derivative and preparation method therefor and use thereof | Pending | 02-Feb-2018 | 000000000 | |
EP-3561048-A1 | Heparinase producing pseudomonas stutzeri strain and heparinase derived therefrom | Pending | 22-Dec-2016 | 00000000 | |
EP-3561048-A4 | Heparinase producing pseudomonas stutzeri strain and heparinase derived therefrom | Pending | 22-Dec-2016 | 00000000 | 0 |
JP-2020501585-A | Heparinase-producing pseudomonas stutzeri strain and heparinase obtained therefrom | Granted | 22-Dec-2016 | 00000000 | 0 |
JP-6863626-B2 | Heparinase-producing pseudomonas stazzeri strain and the heparinase obtained from it | Active | 22-Dec-2016 | C12N9/88 |
Shenzhen Hepalink Pharmaceutical Group Executive Team (4)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Xianqing Xiang | Chief Financial Officer & Vice President, Finance | ||
Tan Li | Board Member & General Manager | ||
Bin Zhang | Vice President, Finance & Executive Director |
Shenzhen Hepalink Pharmaceutical Group Board Members (7)
Name | Representing | Role | Since |
---|---|---|---|
00000 0000 | Self | Board Member | 000 0000 |
00 00 | Shenzhen Hepalink Pharmaceutical Group | Chairman & Board Member | 000 0000 |
000 00 | Shenzhen Hepalink Pharmaceutical Group | Board Member & General Manager | 000 0000 |
Shenzhen Hepalink Pharmaceutical Group Signals
Shenzhen Hepalink Pharmaceutical Group Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Shenzhen Hepalink Pharmaceutical Group Investments & Acquisitions (13)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
00000000000 | 14-Aug-2020 | 0000 | 00.000 | Pharmaceuticals | |
00000000000 | 01-Apr-2019 | 0000 | 000.00 | Pharmaceuticals | |
00000000 0000 | 27-Feb-2018 | 00000 0000 | Other Healthcare Services | 00 00 | |
00000000000 | 04-Dec-2017 | 0000 | 0000 | Pharmaceuticals | |
Resverlogix | 20-Jun-2017 | Public Investment 2nd Offering | 00.000 | Pharmaceuticals |
Shenzhen Hepalink Pharmaceutical Group Subsidiaries (1)
Company Name | Industry | Location | Founded |
---|---|---|---|
00000000 000 | Pharmaceuticals | 0000 |
Shenzhen Hepalink Pharmaceutical Group Exits (3)
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
00000 | 24-Nov-2016 | 00000 00000 00 | 00000 | Completed |
|
000000 00000000000 | 01-Aug-2015 | 00000 00000 00 | 00.000 | Completed |
|
Liminal Biosciences | 08-Jan-2013 | PIPE | 000.00 | Completed |